* Abcellera Biologics Inc ABCL.OQ reported a quarterly
adjusted
loss of 13 cents per share for the quarter ended in June,
lower than the same quarter last year, when the company reported
EPS of -11 cents. The mean expectation of nine analysts for the
quarter was for a loss of 14 cents per share. Wall Street
expected results to range from -16 cents to -13 cents per share.
* Revenue fell 27.2% to $7.32 million from a year ago;
analysts
expected $10.15 million.
* Abcellera Biologics Inc's reported EPS for the quarter was
a
loss of 13 cents.
* The company reported a quarterly loss of $36.93 million.
* Abcellera Biologics Inc shares had fallen by 6.8% this
quarter and lost 51.7% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 11.2%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Abcellera
Biologics Inc is $14.50
This summary was machine generated from LSEG data August 6 at
10:55 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.14 -0.13 Beat
Mar. 31 2024 -0.17 -0.14 Beat
Dec. 31 2023 -0.13 -0.17 Missed
Sep. 30 2023 -0.13 -0.10 Beat